Cystic fibrosis (CF) pathophysiology leads to an increased susceptibility to respiratory infections ([@B8]). The *Burkholderia cepacia* complex (Bcc) prevalence rates in CF patients vary geographically and have been shown to be 1.8% in Belgium ([@B7] and 5% in Canada ([@B2]; in Brazilian children, the prevalence was 4% ([@B25]. CF patients with Bcc infection have high rates of morbidity and mortality ([@B8], [@B15]. Bcc infections pose potential for patient-to-patient transmission, which can lead to the development of "cepacia syndrome," a fatal necrotising pneumonia ([@B8].

Currently, Bcc includes 20 species; however, new species have been identified or reclassified over the years ([@B8], [@B15],[@B26], [@B21], [@B23]. *Burkholderia multivorans* and*Burkhol- deria cenocepacia* were shown to be the prevalent species ([@B8], [@B15]. Correct species identification of Bcc is essential for treating CF patients ([@B10] because of interspecies variation in antimicrobial susceptibility ([@B14] and potential for patient-to-patient transmission ([@B8]. However, accurate Bcc identification is challenging due to the phenotypic and genetic similarities among species.

Bcc species comprise phenotypically indistinguishable microorganisms with high genetic similarity (\> 97.5%) that was determined using 16S rDNA sequencing ([@B5], [@B26]. Conversely, 16S rDNA sequencing assays cannot accurately discriminate among *B. cepacia*, *B. cenocepacia*, *Burkholderia ambifaria*, *Burkholderia pyrrocinia*, and *Burkholderia anthina* (Vermis et al. 2002b). Furthermore, *recA* sequencing data showed that the Bcc interspecies and intraspecies similarities were 94-95% and 98-99%, respectively ([@B28], [@B26]. Thus, Bcc inter and intraspecies discrimination is challenging.

The discriminatory power of *recA* sequencing method is better than 16S rDNA sequencing analysis because *recA* has enough nucleotide variability to enable differentiation of the main Bcc species isolated from CF patients ([@B19]).

Selective media culture and several methods, including phenotypic methods, conventional and automated methods, have been used for Bcc identification. However, reliable and accurate identification of Bcc requires the use of molecular assays such as polymerase chain reaction (PCR)-based assays, PCR-restriction fragment length polymorphism (RFLP-PCR), DNA sequencing, and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF). A study comparing the proficiency of these tests would be valuable for developing a multi-method approach with higher accuracy.

The aim of this study was to compare different methods for identification of Bcc species isolated from oropharyngeal swabs of paediatric CF patients.

SUBJECTS, MATERIALS AND METHODS
===============================

*Bacterial samples* - Oropharyngeal swabs were collected from 46 CF patients (aged 2-90 months) attended at the Cystic Fibrosis Outpatient Clinic of the Department of Paediatrics of the Federal University of Paraná (UFPR) Clinics Hospital from August 2003-February 2009 ([@B25], [@B24]) as previously described ([@B25]).

Fifty-four bacteria samples grown in *B. cepacia* selective agar ([@B11]), presumptively identified as Bcc by polymyxin B susceptibility, oxidase test, and lysine decarboxylation test, were included in the study. Bacteria isolates were kept at -80ºC until subjected to the methods studied.

*Phenotypic identification* - Fifty-four bacterial isolates were subjected to conventional phenotypic tests (CPT) and automated phenotypic tests (APT). CPT was performed as previously described ([@B22]). APT identification was carried out using GN ID cards in the Vitek^®^ 2 Compact system (bioMérieux, USA).

*Susceptibility testing* - Minimum inhibitory concentrations (MICs) of ceftazidime (CAZ), meropenem (MER), levofloxacin (LEV), and sulfamethoxazole/trimethoprim (SUT) were performed (in 36 bacterial isolates) using the agar dilution test protocol described in Clinical and Laboratory Standards Institute (CLSI) M07-A09 (CLSI 2012) and by using interpretive criteria described in CLSI M100-S24 (CLSI 2014). *Pseudomonas aeruginosa* ATCC 27853 and*Escherichia coli* ATCC 25922 were used as control strains.

*Extraction, purification, and quantification of bacterial DNA* - Template DNA of the 54 bacterial isolates was obtained using post-boiling extraction technique ([@B20]) for performing *recA* PCR amplification and RFLP-PCR ([@B19]). AccuPrep Genomic DNA Extraction kit (Bioneer Corporation, Korea) were used for the 36 bacterial isolates subject to *recA* sequencing. The DNA concentrations of samples were quantified using Nano Vue Plus (GE Healthcare Bio-Sciences Corp, USA) and adjusted to concentrations between 20-50 ng/µL.

*PCR for recA* - Primers BCR1 (5′→3′TGAGCCGCCGCAAGAAGAA) and BCR2 (5′→3′CTCTTCCATTTCGTCCTCCGC) ([@B19]) were used for the identification of Bcc. PCR mixture (50 µL) consisted of 1.5 mM MgCl~2~, 0.4 µM of each primer, 0.2 mM each deoxynucleoside triphosphate, 0.02 U/µL Taq DNA polymerase, 1× PCR buffer, 5 µL template DNA (20-50 ng/µL), and 35.5 µL of PCR-grade water. Amplification was performed using Techne TC-412 thermal cycler (Bibby Scientific Ltd, UK) under the following conditions: 1 cycle at 95ºC for 5 min followed by 35 cycles at 95ºC for 30 s, 65ºC for 45 s, and 72ºC for 60 s. The final extension was performed using 1 cycle at 72ºC for 10 min. *B. cepacia* ATCC 17759 and *P. aeru- ginosa* ATCC 27853 were used as positive and negative controls, respectively. The Bcc-positive were confirmed by the presence of a band of approximately 1,040 bp.

*PCR-RFLP for recA* - Amplicons obtained with BCR1 and BCR2 primers were digested with *Hae*III enzyme and each agarose gel (1.5%) electrophoresis profile was compared to those of the following control strains:*B. cenocepacia* IIIA, *B. cenocepacia* IIIB,*Burkholderia stabilis*, *B. multivorans*,*B. cepacia*, and *Burkholderia vietnamiensis* to identify the Bcc species ([@B19]).

*recA sequencing* - The *recA* amplicons were purified with ExoSAP-IT (Affymetrix, USA) and then sequenced using BigDye Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems, USA). The 1,043 bp *recA*gene was sequenced in two fragments of approximately 500 bp using a combination of primers BCR1 (5′→3′TGAGCCGCCGCAAGAAGAA) with BCR4 (5′→3′GCGCAGCGCCTGCGACAT) and BCR2 (5′→3′CTCTTCCATTTCGTCCGCCTC) with BCR3 (5′→3′GTCGCAGGCGCTGCGCAA) ([@B19]). The amplicons were purified using BigDye sequencing X Terminator Purification Kit (Applied Biosystems, Life Technologies Corporation) and sequenced. Each sample generated four sequences that were analysed by using Bioedit software (mbio.ncsu.edu/bioedit/bioedit.html). The obtained consensus sequence was then submitted to PubMLST Bcc allele *recA* database (pubmlst.org/bcc/).

*MALDI-TOF analysis* - MALDI-TOF protein extraction was performed as previously described ([@B12]). The extract was inoculated in duplicate, air-dried, and covered with 1 mL saturated α-cyano-4-hydroxycinnamic acid in 50% acetonitrile and 2.5% trifluoroacetic acid solution. Mass spectra were determined by using Bruker Daltonics Microflex LT instrument with MALDI Biotyper 3.0 software (Bruker Daltonics, Germany), previously calibrated with Bruker Bacterial Test Standard (*Escherichia coli*DH5α) and the mass spectra were generated using a mass range of 2--kDa obtained by ionisation of 240 shots. Species identification and genus were obtained when the scores were ≥ 2.0 and between ≥ 1.7 and \< 2.0, respectively, as recommended by the manufacturer. *B. cepacia* ATCC 25608, *P. aeruginosa* ATCC 27853, and *E. coli* ATCC 25922 were used as controls.

*Statistical analyses* - The analysis of agreement between the methods was performed using the kappa (k) test with criteria outlined by [@B13]: poor agreement (k \< 0), slight agreement (k: 0.01-0.2), reasonable agreement (k: 0.21-0.40), moderate agreement (k: 0.41-0.60), substantial agreement (k: 0.61-0.80), and almost perfect agreement (k: 0.81-1.00). APT and CPT proficiency analyses were performed using contingency table or 2×2 matrix.

*Ethics* - The study design and the consent form were approved by the Clinics Hospital/UFPR Institutional Ethical Review Board.

RESULTS
=======

Thirty-six out of the fifty-four preliminarily identified Bcc strains were confirmed as Bcc by using *recA* PCR amplification. The discordancy in Bcc identification was highlighted by comparative analysis of the findings of the five methodologies (CPT, APT, *recA* PCR, *recA*sequencing, and MALDI-TOF) ([Table I](#t1){ref-type="table"}). Notably, identification of one bacterial isolate did not agree by different techniques: *Bordetella* spp by CPT, *Cupriavidus pauculus* by APT, and as *B. cepacia* by both*recA* sequencing method and MALDI-TOF. One strain of *B. vietnamiensis* could not be conclusively identified by using CPT ([Table I](#t1){ref-type="table"}).

TABLE I*Burkholderia cepacia* complex (Bcc) identification data obtained by using different methodologiesPatientIsolateCPTAPTPCR *recA*Seq.RecA PubMLST Bcc databaseMALDI-TOFAllele *recA*RFLP1BC-48-FC*Bordetella* sp.*Cupriavidus pauculus*Bcc*B. cenocepacia* IIIB*B. cenocepacia*15FBC-5-FCBccBccBcc*B. cepaciaB. cepacia*37E2BC-28-FCBccBccBcc*B. cenocepacia* IIIB*B. cenocepacia*15^*a*^FBC-54-FCBccBccBcc*B. cenocepacia* IIIB*B. cenocepacia*15^*a*^F3BC-25-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^A4BC-32-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^A5BC-46-FCBccBccBcc*B. cenocepacia* IIIB*B. cenocepacia*15^*a*^C6BC-10-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14ABC-15-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^A7BC-1-FCBccBccBcc*B. multivoransB. multivorans*81^*a*^DBC-20-FCBccBccBcc*B. multivoransB. multivorans*81^*a*^D8BC-11-FCBccBccBcc*B. vietnamiensisB. cenocepacia*23^*a*^HBC-18-FCBccBccBcc*B. vietnamiensisB. vietnamiensis*23^*a*^HBC-19-FCBccBccBcc*B. vietnamiensisB. vietnamiensis*23HBC-21-FCBccBccBcc*B. vietnamiensisB. vietnamiensis*23^*a*^HBC-29-FCBccBccBcc*B. vietnamiensisB. vietnamiensis*23^*a*^HBC-42-FCInconclusiveBccBcc*B. vietnamiensisB. vietnamiensis*23^*a*^HBC-58-FCBccBccBcc*B. vietnamiensisB. vietnamiensis*23^*a*^HBC-59-FCBccBccBcc*B. vietnamiensisB. vietnamiensis*23^*a*^HBC-7-FCBccBccBcc*B. vietnamiensisB. vietnamiensis*23^*a*^H9BC-27-FCBccBccBcc*B. cenocepacia* IIIB*B. cenocepacia*15^*a*^F10BC-33-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^ABC-3-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^A11BC-36-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^ABC-56-FCBccBccBcc*B. cenocepacia* IIIB*B. cenocepacia*15^*a*^CBC-60-FCBccBccBcc*B. cenocepacia* IIIB*B. cenocepacia*15^*a*^CBC-61-FCBccBccBcc*B. cenocepacia* IIIB*B. cenocepacia*122C12BC-2-FCBccBccBcc*B. vietnamiensisB. vietnamiensis*48^*a*^I13BC-50-FCBccBccBcc*B. vietnamiensisB. vietnamiensis*48^*a*^I14BC-22-FCBccBccBcc*B. cenocepacia* IIIB*B. cenocepacia*15^*a*^F15BC-34-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^ABC-38-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^ABC-39-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^ABC-41-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^ABC-57-FCBccBccBcc*B. cenocepacia* IIIA*B. cenocepacia*14^*a*^A16BC-52-FCBccBccBcc*B. cenocepacia* IIIB*B. cenocepacia*49^*a*^B[^1]

The *recA* sequencing data and MALDI-TOF data, for the majority of the 36 strains, were in agreement and corroborated with Bcc identification data. However, one strain identified as *B. vietnamiensis* by*recA* sequencing was identified as *B. cenocepacia* by MALDI-TOF ([Table I](#t1){ref-type="table"}).

The identification data obtained by the aforementioned methods were used for performing comparative analyses to assess whether Bcc or Bcc genomic variants were identified consistently. The concordance between phenotypic test data (CPT vs. APT) and that among different tests was also assessed ([Table II](#t2){ref-type="table"}).

TABLE IIEvaluation of agreement among methodsTests (n)^*a*^kSEAgreement^*b*^CPT vs. APT (54)0.8330.080Almost perfect agreementCPT vs. *recA* PCR^*c*^(54)0.8330.080Almost perfect agreementAPT vs. *recA* PCR (54)0.9210.055Almost perfect agreementMALDI-TOF vs. *recA*Seq^*d*^ (36)0.9420.057Almost perfect agreementRFLP^*e*^ vs. *recA* Seq (36)0.5920.099Moderate agreement[^2]

*RecA* amplification data showed almost perfect agreement with CPT data (k: 0.833) and with APT data (k: 0.921). In addition, MALDI-TOF data was also in almost perfect agreement with *recA* sequencing data (k: 0.942). However, PCR-RFLP and *recA* sequencing data presented moderate agreement (k: 0.592). The phenotypic data and the *recA*amplification data were also compared. CPT and APT had assay specificity of 94.44% and 97.62%, respectively ([Table III](#t3){ref-type="table"}). Furthermore, the assay sensitivity of CPT and APT were 81.25% and 100%, respectively ([Table III](#t3){ref-type="table"}).

TABLE IIIA comparative assessment of automated phenotypic tests (APT) and conventional phenotypic tests (CPT) proficiency for *Burkholderia cepacia* complex (Bcc) identificationTestSensitivity (%)Specificity (%)PPV (%)NPV (%)APT97.6210010094.12CPT94.4481.2591.8986.67[^3]

PCR-RFLP analysis of 36 isolates resulted in nine different restriction profiles. Three different patterns (B, C, and F) were obtained for *B. cenocepacia* IIIB and one for *B. cenocepacia* IIIA (pattern A). Pattern D was associated with *B. multivorans*. The pattern E was linked with *B. cepacia*. Two patterns (H and I) were related to *B. vietnamiensis*. The pattern G corresponded to C12*B. stabilis* control.

Our data showed prevalence rate of 33.4% (12/36) for *B. cenocepacia*IIIA, 30.6% (11/36) for *B. vietnamiensis*, 27.8% (10/36) for*B. cenocepacia* IIIB, 5.5% (2/36) for *B. multivorans*, and 2.7% (1/36) for *B. cepacia*.

Antimicrobial susceptibility testing data presented as follows: the *B. cepacia* isolate was susceptible to all antimicrobial agents tested; all*B. cenocepacia* (22/22) were susceptible to CAZ, LEV, and MER, and 68.2% (15/22) were susceptible to SUT; all *B. multi-vorans*(2/2) showed sensitivity to LEV, CAZ, and MER, but presented resistance to SUT; all*B. vietnamiensis* (11/11) were sensitive to LEV, 81.8% (9/11)*B. vietna- miensis* were sensitive to CAZ, 90.9% (10/11)*B. vietnamiensis* isolates were sensitive to MER, and 72.7% (8/11) *B. vietnamiensis* isolates were sensitive to SUT.

DISCUSSION
==========

Owing to the similarity in phenotypic characteristics of Bcc species, interspecies distinction is challenging ([@B26]). A comparative analysis between CPT and APT was performed using k test and the results indicated that the findings were in agreement; however, it is important to note that the quality of the CPT results depends on the experience and expertise of the microbiologist. A comparative analysis of phenotypic test data and*recA* amplification data indicated that CPT and APT data were in agreement with *recA* amplification data; however, the positive predictive value, specificity, and the k coefficient of APT was higher than that of CPT. Thus, APT may be a better test than CPT for Bcc identification. Although APT cannot adequately perform Bcc interspecies distinction, it could be used for Bcc identification in laboratories lacking molecular biology facilities.

MALDI-TOF proved to be a useful tool for identification of Bcc species obtained from CF patients, although it was not able to identify *B. cenocepacia*subtypes. This finding corroborated those from other studies ([@B1], [@B9]. MALDI-TOF is a rapid and single step assay that does not require personnel with assay expertise. Furthermore, MALDI-TOF and*recA* sequencing assays have comparable Bcc identification accuracy ([@B1], [@B9].

Studies have shown that *recA* PCR using species-specific primers is not sensitive and specific ([@B6], [@B17], [@B26]) and sequencing is required for the final identification ([@B18], Vermis et al. 2002a). Comparison between PCR-RFLP and *recA* sequencing data indicates only moderate correlation between the findings of the two methods. Other studies have shown that*Hae*III RFLP patterns insufficiently discriminated *B. cepacia*, *B. cenocepacia*, and *B. stabilis*([@B27], [@B20]. Previous studies demonstrated the limited usefulness of PCR-RFLP technique for discriminating Bcc: the same variants may have different genomic restriction patterns, one restriction pattern can be associated with different species, and interlaboratory reproducibility is impaired because more than 70*recA*-*Hae*III restriction patterns have been identified. In addition, the requirement of a standard control for each species and its subtypes become the precise identification of each isolate not practical ([@B28], [@B26]. Although the results suggest the optimal performance of MALDI-TOF of Bcc species identification, some studies indicate a certain difficulty of this method to differentiate some strains of*B. cepacia* and *B. cenocepacia* ([@B26], [@B20].

This study found the highest prevalence rates for *B. cenocepacia* and this finding was similar to those reported in epidemiological studies of patients with CF and Bcc ([@B18], [@B8], [@B15]. The prevalence of *B. cenocepacia* IIIA determined in our study was similar to that reported in Canada, UK, Italy, and other European countries, while IIIB is prevalent in United States of America (USA) ([@B18]. However, higher *B. multivorans* prevalence in CF centres in the UK and the USA has been recently reported and the increased prevalence may be due to the approaches taken in these centres to control *B. cenocepacia* outbreaks ([@B17], [@B8], [@B15]. *B. vietnamiensis* was identified as the second most prevalent genomic variant and these findings were in agreement with those of a previous study ([@B16].

Antimicrobial susceptibility data showed that the isolates were highly resistant to SUT. Amongst the isolated Bcc species, *B. vietnamiensis* showed a higher percentage of resistance to all antibiotics than that displayed by the other species identified in our study and these findings contradicted previous findings ([@B30]), which showed that*B. vietnamiensis* was the most sensitive species among the 142 clinical and environmental Bcc samples. Prolonged and aggressive antibiotic therapy is required for treatment of patients with Bcc chronic infection ([@B14]). Therefore, antibiotic susceptibility pattern data for local Bcc strains are important because these microorganisms have intrinsic resistance and develop in vivo resistance to several classes of antimicrobials and thereby limit the effectiveness of empirical antibiotic therapy ([@B8]). In conclusion, a polyphasic approach that combines biochemical and molecular tests is required to accurate identification of Bcc species infecting CF patients. In the studied population, *B. cenocepacia* was the prevalent species, predominantly IIIA subtype. Identification by MALDI-TOF and sequencing of *recA* agreed in 97.2% of the isolates. Although MALDI-TOF results completely agree with the results of *recA*sequencing for the majority of the strains, it proved not to be able to identify*B. cenocepacia* subtypes. Between the two phenotypic assays, APT was determined to be a better analytical method than CPT was and can be used in laboratories without molecular assay facilities. However, phenotypic assays were not useful for Bcc species differentiation. *B. vietnamiensis* was the Bcc species resistant to the higher number of antimicrobials. SUT was the antimicrobial with the highest percentage of resistance. The high degree of antimicrobial susceptibility obtained in our study may be due the fact that the studied strains are from outpatient, possibly undergoing minor antimicrobial selective pressure.

To Bruker Corporation of Brazil, for support in the MALDI-TOF.

[^1]: *a*: exact *recA* allele match; APT: automated phenotypic tests; CPT: conventional phenotypic tests; MALDI-TOF: matrix-assisted laser desorption ionization-time of flight; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism.

[^2]: *a*: number of isolates tested by each test;*b*: adapted interpretation criteria ([@B13]);*c*: amplification of *recA*;*d*: sequencing of *recA*;*e*: *Hae*III-restriction fragment length polymorphism (RFLP) *recA*; APT: automated phenotypic tests; CPT: conventional phenotypic tests; k: kappa index; MALDI-TOF: matrix-assisted laser desorption ionization-time of flight; PCR: polymerase chain reaction; SE: standard error.

[^3]: analysis performed with 54 isolates presumptively identified as Bcc. NPV: negative predictive value; PPV: positive predictive value.
